Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1167521

registered interest
date	30/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the implications for his policy of the report entitled, A Hidden Harm: Why healthcare professionals want to stop unfair asthma prescription charges published by Asthma UK with the Royal College of Nursing, Association of Respiratory Nurse Specialists and Primary Care Respiratory Society.
tabling member constituency	High Peak
tabling member printed	Ruth George
uin	7799
answer	answer is ministerial correction date of answer 04/11/2019 answer text <p>The Department has no plans to change the list of medical exemptions from prescription charges. Extensive arrangements are already in place to help people access National Health Service prescriptions. These include a broad range of NHS prescription charge exemptions for which someone with asthma may qualify.</p><p>People on a low income, who do not qualify for an exemption, may be eligible for full or partial help with prescription charges through application to the NHS Low Income Scheme.</p><p>To support those with the greatest need who do not qualify for an exemption, the cost of the prescription pre-payment certificates has been frozen for another year. A holder of a 12-month certificate can get all the prescriptions they need for just £2 per week.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 04/11/2019 17:33:56 answering member 4380 label Biography information for Jo Churchill
tabling member	4662 label Biography information for Ruth George

1148858

registered interest
date	14/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Reciprocal Arrangements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 9 September 2019 to Question 284706, what advice the Government has issued to UK citizens travelling in the EU that require treatments not routinely covered by travel insurance policies after the UK leaves the EU.
tabling member constituency	High Peak
tabling member printed	Ruth George
uin	324
answer	answer is ministerial correction date of answer 17/10/2019 answer text <p>The United Kingdom Government has proposed to all Member States that we should maintain existing reciprocal healthcare arrangements until 31 December 2020 if the UK leaves the European Union without a deal. This includes the European Health Insurance Card (EHIC) which can support UK residents with long term conditions travelling to the EU who may require needs arising treatment.</p><p>The Government understands the concerns of patients with long term conditions and is working to secure the continuation of reciprocal healthcare arrangements, so UK and EU nationals have access to medical treatment in the same way they do now.</p><p>Guidance for travelling to the EU after EU exit is available on gov.uk, available at the following link:</p><p><a href="https://www.gov.uk/guidance/uk-residents-visiting-the-eueea-and-switzerland-healthcare" target="_blank">https://www.gov.uk/guidance/uk-residents-visiting-the-eueea-and-switzerland-healthcare</a></p><p>The UK Government is advising people with pre-existing or long term medical conditions to also check the Money and Pensions Advice Service which has information on their website for people about their options for purchasing travel insurance. Further information is available at the following link:</p><p><a href="http://www.moneyadviceservice.org.uk/en/articles/travel-insurance-for-over-65s-and-medical-conditions" target="_blank">www.moneyadviceservice.org.uk/en/articles/travel-insurance-for-over-65s-and-medical-conditions</a></p> answering member constituency Charnwood answering member printed Edward Argar question first answered 17/10/2019 09:40:57 answering member 4362 label Biography information for Edward Argar
tabling member	4662 label Biography information for Ruth George

1148860

registered interest
date	14/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that there will be no shortage of the medicines and consumables needed for dialysis or transplantation following the UK’s departure from the EU.
tabling member constituency	High Peak
tabling member printed	Ruth George
uin	325
answer	answer is ministerial correction date of answer 17/10/2019 answer text <p>The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products once we have left the EU.</p><p>The Department, as part of our EU exit preparations, continues to implement a multi-layered approach to mitigate potential disruption to supply, which includes medicines and consumables needed for dialysis or transplantation. This approach consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:</p><p><a href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans" target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a></p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 17/10/2019 09:44:50 answering member 4362 label Biography information for Edward Argar
tabling member	4662 label Biography information for Ruth George

1148861

registered interest
date	14/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Explanatory Memorandum to The Human Medicines (Amendment) Regulations 2019, 7.12, whether in the event of a Serious Shortage Protocol being issued for immunosuppressant medicines patients would always be referred back to the prescriber for any decision on their treatment before any therapeutic or generic alternative is supplied.
tabling member constituency	High Peak
tabling member printed	Ruth George
uin	326
answer	answer is ministerial correction date of answer 22/10/2019 answer text <p>While Serious Shortage Protocols (SSP) in England have the scope to cover all medicines and appliances that are on a National Health Service prescription in primary care, including immunosuppressant medicines, it is clear that an SSP for therapeutic or generic equivalents will not necessarily be suitable for all medicines and patients. For example, where medicines need to be prescribed by brand for clinical reasons, which may be the case for certain immunosuppressant medicines. In these cases, patients would always be referred back to the prescriber for any decision about their treatment before any alternative is supplied.</p><p>Any protocol would however only be introduced if clinicians with expertise in the relevant area think it is appropriate. So, if an SSP for an immunosuppressant medicine was under consideration, this would be agreed with, for example, transplant specialists or other relevant clinicians. Pharmacists will have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate or the patient should be referred to their prescriber.</p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/10/2019 11:21:30 answering member 4380 label Biography information for Jo Churchill
tabling member	4662 label Biography information for Ruth George